Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Colon Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 35 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab | Phase 3 | Phase 3 | 7 | 2 | 1 | 13 | 0 | — | — | Aug 17, 2015 |
| Cetuximab | Phase 3 | Phase 3 | 6 | 1 | 4 | 32 | 0 | — | — | 2003-12 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 4 | 1 | 2 | 6 | 0 | — | — | 2014-10 |
| Leucovorin | Phase 3 | Phase 3 | 3 | 0 | 14 | 42 | 0 | — | — | 1993-11 |
| CAPOX Regimen | Phase 3 | Phase 3 | 3 | 2 | 1 | 6 | 0 | — | — | Jun 16, 2020 |
| Fruquintinib | Phase 3 | Phase 3 | 3 | 1 | 1 | 5 | 0 | — | — | Dec 11, 2017 |
| Encorafenib | Phase 3 | Phase 3 | 3 | 0 | 1 | 4 | 0 | — | — | Jun 14, 2019 |
| Panitumumab | Phase 3 | Phase 3 | 2 | 1 | 2 | 15 | 0 | — | — | 2004-12 |
| Aspirin | Phase 3 | Phase 3 | 2 | 0 | 3 | 6 | 0 | — | — | 2007-03 |
| Ipilimumab | Phase 3 | Phase 3 | 2 | 2 | 1 | 6 | 0 | — | — | 2013-02 |
| Trastuzumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Pertuzumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 4 | 0 | — | — | 2007-10 |
| Atezolizumab | Phase 3 | Phase 3 | 2 | 1 | 2 | 2 | 0 | — | — | Oct 16, 2017 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 1 | 1 | 2 | 6 | 0 | — | — | 2004-12 |
| Celecoxib | Phase 3 | Phase 3 | 1 | 1 | 1 | 5 | 0 | — | — | 2000-03 |
| Temozolomide | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Jan 15, 2019 |
| Immunomodulatory Oligonucleotide | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Apr 15, 2026 |
| Levoleucovorin | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2002-10 |
| Pegfilgrastim | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Feb 1, 2003 |
| Avelumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Aug 31, 2018 |
| Chemotherapy | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Nov 3, 2009 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.